Tyra Biosciences, Inc. Share Price
TYRATyra Biosciences, Inc. Stock Performance
Open $28.01 | Prev. Close $28.97 | Circuit Range N/A |
Day Range $27.91 - $28.98 | Year Range $6.42 - $33.96 | Volume 28,006 |
Average Traded $28.41 |
Tyra Biosciences, Inc. Share Price Chart
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Tyra Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
17-Feb-26 | $28.01 | $28.97 | +0.00% |
17-Feb-26 | $28.01 | $28.97 | +3.52% |
13-Feb-26 | $29.21 | $27.98 | -3.73% |
12-Feb-26 | $33.96 | $29.07 | -3.04% |
11-Feb-26 | $31.46 | $29.98 | -4.46% |
10-Feb-26 | $30.56 | $31.38 | +2.92% |
09-Feb-26 | $30.44 | $30.49 | -1.71% |